公开(公告)号：US20240415819A1

公开(公告)日：2024-12-19

申请号：US18694432

申请日：2022-09-25

Applicant: Lead Discovery Center GmbH ,  QLI5 THERAPEUTICS AG

Inventor： Uwe Koch ,  Gunther Zischinsky ,  Anke Unger ,  Peter Nussbaumer ,  Bert Klebl ,  Axel Choidas ,  Klaus Dinkel ,  Julian Engel ,  Carsten Degenhart ,  Robert Huber ,  Kiyean Nam ,  Jaesung Kim ,  Jeongjea Seo ,  Seung-Joo Lee ,  Yeejin Jeon ,  Wongyun Ahn

IPC: A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61P35/00 ,  C07D498/08 ,  C07D519/00

Abstract: The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease.